InvestSMART

Bioxyne Limited (ASX:BXN)

ALERT: Price-sensitive ASX Announcement for BXN
Current share price for BXN : $0.930 0.853 (1,107.79%)+
Announcement
Release
21 Apr 2026 8:33AM
Price at Release
$0.077
Full Release
download
Summary
Bioxyne Limited, an Australian pharmaceutical company, reported significant financial improvements for the quarter ending 31 March 2026, with a record revenue of $21.3 million and a $20.9 million increase in cash receipts from operations. The company achieved a positive cash flow from operations, reflecting ongoing investments in working capital and growth strategies. Key developments include a manufacturing agreement with Aurora Cannabis for medicinal cannabis oils and initial orders for psilocybin capsules for research purposes. With $8.5 million cash on hand and strategic initiatives in place, the company is positioned for further domestic and international expansion, particularly in the UK and Germany.
Key Points
  • Bioxyne Limited reported a record $21.3 million quarterly revenue, up 137% compared to the previous corresponding period.
  • The company noted a $20.9 million increase in quarterly cash receipts, a 146% rise from the prior corresponding period.
  • Positive cash flow from operating activities was $1.2 million, supporting business growth.
  • A manufacturing agreement was signed with Aurora Cannabis for supplying medicinal cannabis oils.
  • Initial purchase orders received for GMP-manufactured psilocybin capsules for mental health research.
  • Bioxyne has $8.5 million cash on hand as of 31 March 2026.
  • The quarterly results were driven by increased demand for medicinal cannabis and psychedelic products.
  • Bioxyne's future outlook includes further domestic growth and international expansion into the UK and Germany.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.